Treatment of negative and cognitive schizophrenia symptoms based on combined activation of mGlu2/M4 receptors creates new possibilities for the use of mGlu2 receptor ligands, which have been considered novel psychotropic drugs for years, exhibiting only slight success. This evidence concerns the gene GRM2 and schizophrenia.